IPSEN (OTCMKTS:IPSEY) Stock Short Interest Climbs 3,378.0%

IPSEN (OTCMKTS:IPSEY) was the target of a large growth in short interest in September. As of September 30th, there was short interest totaling 1,426 shares, a growth of 3,378.0% from the September 15th total of 41 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average trading volume of 626 shares, the short-interest ratio is presently 2.3 days.

Wall Street Analysts Forecast Growth

IPSEY has been the topic of several research analyst reports. Jefferies Financial Group cut IPSEN from a “hold” rating to a “moderate sell” rating in a research note on Sunday, August 2nd. Barclays raised IPSEN from a “strong sell” rating to a “hold” rating in a research report on Thursday, September 17th. Finally, HC Wainwright reiterated a “buy” rating on shares of IPSEN in a report on Tuesday, June 30th. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, IPSEN has an average rating of “Hold”.

IPSEN Stock Up 1.3%

Shares of OTCMKTS IPSEY opened at $40.65 on Friday. IPSEN has a 12-month low of $32.68 and a 12-month high of $51.10. The stock’s fifty day simple moving average is $45.18 and its two-hundred day simple moving average is $46.27.

IPSEN Company Profile

Ipsen SA is a France-based biopharmaceutical company focused on the discovery, development and commercialization of medicines in specialty care. Its principal therapeutic areas are oncology, rare diseases and neuroscience, with an emphasis on treatments for conditions that often have limited therapeutic options.

The company’s portfolio includes Somatuline (lanreotide) for certain neuroendocrine tumors and endocrine disorders, Dysport (abobotulinumtoxinA) for selected movement disorders and aesthetic applications, and cancer treatments such as Cabometyx and Onivyde.